These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 23921833)
1. Association between depot medroxyprogesterone acetate (DMPA), physical activity and bone health. Babatunde OO; Forsyth JJ J Bone Miner Metab; 2014 May; 32(3):305-11. PubMed ID: 23921833 [TBL] [Abstract][Full Text] [Related]
2. Bone density in women receiving depot medroxyprogesterone acetate for contraception. Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502 [TBL] [Abstract][Full Text] [Related]
3. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077 [TBL] [Abstract][Full Text] [Related]
4. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors. Taneepanichskul S; Intaraprasert S; Theppisai U; Chaturachinda K Contraception; 1997 Jul; 56(1):1-3. PubMed ID: 9306024 [TBL] [Abstract][Full Text] [Related]
5. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate. Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135 [TBL] [Abstract][Full Text] [Related]
6. Bone mineral density testing, and bisphosphonate and oestrogen prescribing associated with depot medroxyprogesterone acetate utilization-The impact of the boxed warning. Eworuke E; Popat V; Moeny DG J Clin Pharm Ther; 2017 Aug; 42(4):483-494. PubMed ID: 28543135 [TBL] [Abstract][Full Text] [Related]
7. Trabecular bone in long-term depot-medroxyprogesterone acetate users. Virutamasen P; Wangsuphachart S; Reinprayoon D; Kriengsinyot R; Leepipatpaiboon S; Gua C Asia Oceania J Obstet Gynaecol; 1994 Sep; 20(3):269-74. PubMed ID: 7811192 [TBL] [Abstract][Full Text] [Related]
8. Bone density in long term users of depot medroxyprogesterone acetate. Gbolade B; Ellis S; Murby B; Randall S; Kirkman R Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421 [TBL] [Abstract][Full Text] [Related]
9. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Clark MK; Sowers MR; Nichols S; Levy B Fertil Steril; 2004 Dec; 82(6):1580-6. PubMed ID: 15589863 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate. Modesto W; Bahamondes MV; Bahamondes L J Womens Health (Larchmt); 2015 Aug; 24(8):636-40. PubMed ID: 26098552 [TBL] [Abstract][Full Text] [Related]
11. Exploratory study of the effect of lifestyle counselling on bone mineral density and body composition in users of the contraceptive depot-medroxyprogesterone acetate. Modesto W; Bahamondes MV; Silva dos Santos P; Fernandes A; Dal'Ava N; Bahamondes L Eur J Contracept Reprod Health Care; 2014 Aug; 19(4):244-9. PubMed ID: 24923792 [TBL] [Abstract][Full Text] [Related]
12. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report. Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754 [TBL] [Abstract][Full Text] [Related]
14. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Paiva LC; Pinto-Neto AM; Faundes A Contraception; 1998 Dec; 58(6):351-5. PubMed ID: 10095971 [TBL] [Abstract][Full Text] [Related]
15. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Kyvernitakis I; Kostev K; Nassour T; Thomasius F; Hadji P Osteoporos Int; 2017 Jan; 28(1):291-297. PubMed ID: 27461017 [TBL] [Abstract][Full Text] [Related]
16. Bone mineral density in women of a low socioeconomic level using DMPA for contraception in rural Upper Egypt. Hussein M; Mahran DG; Farouk OA; El-Assal MA; Fathallah MM; Romih MS Int J Gynaecol Obstet; 2010 Jul; 110(1):31-4. PubMed ID: 20347086 [TBL] [Abstract][Full Text] [Related]
17. Long-term depot-medroxyprogesterone acetate and bone mineral density. Tang OS; Tang G; Yip P; Li B; Fan S Contraception; 1999 Jan; 59(1):25-9. PubMed ID: 10342083 [TBL] [Abstract][Full Text] [Related]
18. Body weight and body composition of depot medroxyprogesterone acetate users. Dal'Ava N; Bahamondes L; Bahamondes MV; Bottura BF; Monteiro I Contraception; 2014 Aug; 90(2):182-7. PubMed ID: 24780631 [TBL] [Abstract][Full Text] [Related]
19. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review. Dragoman MV; Gaffield ME Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275 [TBL] [Abstract][Full Text] [Related]
20. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Naessen T; Olsson SE; Gudmundson J Contraception; 1995 Jul; 52(1):35-9. PubMed ID: 8521712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]